Volume 4, Issue 2 (April 2025)
Health Science Monitor 2025, 4(2): 157-165 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mahmoudzadeh H, Ghafouri Y, Houshmand H R, Ghaemi S R. Investigation of demographic, clinical, laboratory features, and outcomes of children with serum sickness hospitalized in a hospital. Health Science Monitor 2025; 4 (2) :157-165
URL: http://hsm.umsu.ac.ir/article-1-217-en.html
URL: http://hsm.umsu.ac.ir/article-1-217-en.html
Department of Pediatric Disease, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Abstract: (121 Views)
Background & Aims: Serum sickness is a type 3 hypersensitivity reaction caused by the injection of foreign proteins, serums, and non-protein medications. This study investigated the demographic, clinical, and laboratory characteristics, along with outcomes, of patients with serum sickness hospitalized at Shahid Motahari Hospital, Urmia, from March 2017 to February 2021.
Materials & Methods: This descriptive cross-sectional study included 67 patients diagnosed with serum sickness based on a recent history of exposure to an antigenic substance. Demographic, clinical, paraclinical data, and disease outcomes—including hospital stay length, ICU admission history, treatment response, mortality, and information regarding the potential cause of the disease—were collected from patient records, recorded in a checklist, and analyzed using SPSS statistical software version 22.
Results: Arthralgia was present in 20 patients (29.9%), gastrointestinal complaints in nine children (13.4%), headaches in eight children (11.9%), muscle pain in 18 children (26.9%), arthritis in 14 children (20.9%), and urinary symptoms in one child (1.5%). The most frequent cause of serum sickness was phenobarbital, identified in 26 patients (38.8%), followed by cefixime in nine patients (13.4%), azithromycin in six patients (9%), ceftriaxone in five patients (7.5%), and co-amoxiclav in four patients (6%). Additionally, leukocytosis was found in 23 patients (34.3%), 32 patients (47.8%) had a positive C-reactive protein (CRP), 32 patients (47.8%) had an elevated erythrocyte sedimentation rate (ESR), same as sedimentation rate, and elevated aspartate aminotransferase (AST) and alanine transaminase (ALT) were detected in 4 patients (6%) each.
Conclusion: Clinically, serum sickness was most commonly associated with fever, skin rashes, muscle pain, and changes in paraclinical findings in patients.
Materials & Methods: This descriptive cross-sectional study included 67 patients diagnosed with serum sickness based on a recent history of exposure to an antigenic substance. Demographic, clinical, paraclinical data, and disease outcomes—including hospital stay length, ICU admission history, treatment response, mortality, and information regarding the potential cause of the disease—were collected from patient records, recorded in a checklist, and analyzed using SPSS statistical software version 22.
Results: Arthralgia was present in 20 patients (29.9%), gastrointestinal complaints in nine children (13.4%), headaches in eight children (11.9%), muscle pain in 18 children (26.9%), arthritis in 14 children (20.9%), and urinary symptoms in one child (1.5%). The most frequent cause of serum sickness was phenobarbital, identified in 26 patients (38.8%), followed by cefixime in nine patients (13.4%), azithromycin in six patients (9%), ceftriaxone in five patients (7.5%), and co-amoxiclav in four patients (6%). Additionally, leukocytosis was found in 23 patients (34.3%), 32 patients (47.8%) had a positive C-reactive protein (CRP), 32 patients (47.8%) had an elevated erythrocyte sedimentation rate (ESR), same as sedimentation rate, and elevated aspartate aminotransferase (AST) and alanine transaminase (ALT) were detected in 4 patients (6%) each.
Conclusion: Clinically, serum sickness was most commonly associated with fever, skin rashes, muscle pain, and changes in paraclinical findings in patients.
Type of Study: Research |
Subject:
General
Received: 2024/12/29 | Accepted: 2025/04/29 | Published: 2025/04/30
Received: 2024/12/29 | Accepted: 2025/04/29 | Published: 2025/04/30
References
1. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM. A prospective clinical and immunologic analysis of patients with serum sickness. The New England Journal of Medicine. 1984;311(22):1407-13. [DOI] [PMID]
2. Clark BM, Kotti GH, Shah AD, Conger NG. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy. 2006;26(5):705-8. [DOI] [PMID]
3. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. Journal of Clinical Rheumatology. 2007;13(2):94-5. [DOI] [PMID]
4. Suwansrinon K, Jaijareonsup W, Wilde H, Benjavongkulchai M, Sriaroon C, Sitprija V. Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101(2):206-8 [DOI] [PMID]
5. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. American Medical Association. 1995;273(12):934-41. [DOI] [PMID]
6. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. 2004;2(7):542-53 [DOI] [PMID]
7. Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis. Academic Emergency Medicine. 2012;19(2):121-31. [DOI] [PMID]
8. Lieberman P, Rice MC, Mallette JE. Studies of urticaria and acute serum sickness with the C1q precipitin test. Archives of internal medicine. 1977;137(4):440-2. [DOI] [PMID]
9. Arkachaisri T. Serum sickness and hepatitis B vaccine including review of the literature. The Journal of the Medical Association of Thailand. 2002;85 Suppl 2:S607-12. [Google Scholar]
10. Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Practice & Research Clinical Gastroenterology. 2009;23(1):101-12. [DOI] [PMID]
11. Benson E. Bupropion-induced hypersensitivity reactions. Medical Journal of Australia. 2001; 174(12):650-1. [DOI] [PMID]
12. Wooltorton E. Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. Canadian Medical Association Journal. 2002;166(1):68. [Google Scholar]
13. Tan MG, Burns BF, Glassman SJ. Serum sickness-like reaction associated with mirabegron. Journal of the American Academy of Dermatology Case Reports. 2019;(6):537-539. [DOI] [PMID] [PMCID]
14. Suwansrinon K, Jaijareonsup W, Wilde H, Benjavongkulchai M, Sriaroon C, Sitprija V. Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101(2):206-8. [DOI] [PMID]
15. Frank MM, Hester CG. Immune Complex-Mediated Diseases. Adkinson NF Jr, Bochner BS, Burks W, et al, Eds. Middleton's Allergy Principles and Practice. 8th ed. Philadelphia PA: Saunders. 2014;602-16. [DOI] [PMID]
16. Pichler WJ. Drug hypersensitivity. Rich RR, ed. Clinical Immunology Principles and Practice. 4th ed. St Louis, Mo: Elsevier/Saunders. 2013; 564-77. [DOI]
17. Shiyari R, Gholamiyan R, Chavosh Zadeh Z, Hatamiyan B. Investigation of Serum sickness etiology and frequency among pediatric patients reffered to Mofid pediatric hospital. The journal of allergy and clinical immunology. 2008;26(4):510-4. [Google Scholar]
18. Misirlioglu ED, Duman H, Ozmen S, Bostanci I. Serum sickness-like reaction in children due to cefditoren. Pediatric Dermatology. 2012;29(3):327-8. [DOI] [PMID]
19. Mirsaeid G, Dibaei M, Salamati P, Rahbarimanesh A.A, Akhlaghi H, Adverse drug reactions as a cause for admissions to a childrens hospital. Iranian journal of pediatrics. 2007;17(1): 11-14.
20. Erffmeyer JE. Serum sickness. Annals of Allergy, Asthma & Immunology. 1986;56(2):1059. [Google Scholar]
21. Omidian M, Sheikh Davoudi N, Mousavi Z.B, Survey prevalence of cutaneous eruption and incriminate drugs in 110 patiens, Jundishapur scientific medical journal. 2010;8(4):431-436. [Google Scholar]
22. Maeda R, Kawasaki Y, Ohara S, Suyama K, Hosoya M. Serum sickness with refractory nephrotic syndrome following treatment with rituximab. Soci- ety of Nephrology Case Reports. 2018;7(1):69-72. [DOI] [PMID] [PMCID]
23. Ryan NM, Kearney RT, Brown SG, Isbister GK. Incidence of serum sickness after the administration of Australian snake antivenom (ASP-22). Clinical toxicology (Philadelphia, Pa.). 2016;54(1):27-33. [DOI] [PMID]
24. Bayer G, Agier MS, Lioger B, Lepelley M, Zenut M, Lanoue MC, Maillot F, Jonville-Bera AP. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. European Journal of Internal Medicine. 2019;67:59-64. [DOI] [PMID]
25. Yorulmaz A, Akın F, Sert A, Ağır MA, Yılmaz R, Arslan Ş. Demographic and clinical characteristics of patients with serum sickness-like reaction. Clinical Rheumatology. 2018;37(5):1389-1394. [DOI] [PMID]
26. Kurukulaaratchy RJ, Karmaus W, Arshad SH. Sex and atopy influences on the natural history of rhinitis. Current Opinion in Allergy and Clinical Immunology. 2012;12:7-12. [DOI] [PMID] [PMCID]
27. Pinart M, Keller T, Reich A, Fröhlich M, Cabieses B, Hohmann C, et al. Sex-related allergic rhinitis prevalence switch from childhood to adulthood: a systematic review and meta-analysisInternational Archives of Allergy and Immunology. 2017;172:224-235. [DOI] [PMID]
28. Frohlich M, Pinart M, Kekker T, Cabieses B, Hohmann C, Postma D, et al. Is there a sex- shift in prevalence of allergic rhinitis and comorbid asthma from childhood to adulthood?. A meta- analysis. Clinical and Translational Allergy. 2017;7:44. [DOI] [PMID] [PMCID]
29. Sharma VK, Sethuraman G, kumear B. Cotaneous adverse drug reactions: Clinical pattern and causative agents, A 6 years Series from chandigarh, India. Postgraduate Medical Journal, 2001;47:95-9. [Google Scholar]
30. Sushma M, Noel MV, Ripika MC, Jamef J, Guido S. Cutaneous adverse drug reactions: A 9 Year Study from a South Indian hospital. Safety. 2005;14(8):567-70. [DOI] [PMID]
31. Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children afterantibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. American Journal of Epidemiology. 1990;132(2): 336-42. [DOI] [PMID]
32. Kojis F G. Serum sickness and anaphylaxis: Analysis of cases of 6211 patients treated with horse serum for various infectious. The American Journal of Diseases of Children. 1942;64:93-143. [DOI]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
